SynthesisFrontiers in medicine2025
Efficacy and safety of mirikizumab (LY3074828) in chronic plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic plaque psoriasis is a persistent inflammatory skin condition characterized by erythematous, scaly plaques, significantly impairing the quality of life of affected individuals. Mirikizumab, a humanized monoclonal antibody targeting interleukin-23 (IL-23) p19 subunit, has shown promising efficacy in managing moderate-to-severe cases of this disease. This meta-analysis aims to evaluate the efficacy and safety of mirikizumab in comparison to placebo or other active treatments in this patient population. Methods: A systematic review of randomized controlled trials (RCTs) was conducted. Eligible studies were identified through searches of major databases. The primary endpoint was clinical response measured by Psoriasis Area and Severity Index (PASI) improvement. Safety outcomes were evaluated based on the frequency of events. Data were pooled using a random-effects model to calculate relative risk and mean differences across studies. Results: Mirikizumab significantly increased the rates of achieving PASI 100, PASI 90, and PASI 75 compared to placebo. Mirikizumab also demonstrated superior efficacy in various secondary outcomes compared to placebo. Safety analysis indicated no significant differences in overall treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs), although upper respiratory tract infections occurred more frequently in the mirikizumab group. Conclusion: Mirikizumab demonstrated a significant improvement in PASI scores compared to placebo and other treatments for chronic plaque psoriasis. Its IL-23 inhibition mechanism suggests a promising therapeutic option with a favorable safety profile. Further research could solidify its position in long-term psoriasis management. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier [CRD42024594843].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.